Sugi Predict

Sugi Predict / Compounds / SCHEMBL18151053

SCHEMBL18151053

SCHEMBL18151053

CS(=O)(=O)c1cccc(-c2ccc3nc4n(c3c2)C(c2ccccc2)CC4)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RIPK1 Q13546 3/20 0.45
▸ PIK3CB P42338 1/20 0.43
▸ MTOR P42345 1/20 0.43
▸ PRKDC P78527 1/20 0.43
▸ ATM Q13315 1/20 0.43
▸ ATR Q13535 1/20 0.43
▸ ATRIP Q8WXE1 1/20 0.43
▸ OPRM1 P35372 1/20 0.42
▸ OPRL1 P41146 1/20 0.42
▸ DRD2 P14416 1/20 0.40
▸ KCNH2 Q12809 1/20 0.39
▸ NR1H2 P55055 7/20 0.39
▸ NR1H3 Q13133 5/20 0.39
▸ SCD O00767 2/20 0.38
▸ RXRA P19793 2/20 0.38
▸ CPT2 P23786 1/20 0.37
▸ CPT1A P50416 1/20 0.37
▸ NPBWR1 P48145 1/20 0.37
▸ GRIA2 P42262 1/20 0.36
▸ VCP P55072 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18150867 0.92 RIPK1 (0.46) RIPK1KCNH2SCD
SCHEMBL18151397 0.89 PIK3CB (0.44) RIPK1PIK3CBMTORPRKDCATM
SCHEMBL18162358 0.84 RIPK1 (0.43) RIPK1PIK3CB
SCHEMBL29795024 0.84 RIPK1 (0.43) RIPK1PIK3CB
SCHEMBL31292036 0.84 RIPK1 (0.43) RIPK1PIK3CB
SCHEMBL18151041 0.84 RIPK1 (0.43) RIPK1PIK3CB
SCHEMBL18150952 0.83 RIPK1 (0.48) RIPK1
SCHEMBL18151008 0.83 CA2 (0.43) RIPK1ATM
SCHEMBL29794891 0.82 CPT2 (0.42) RIPK1CPT2CPT1A
SCHEMBL18151545 0.82 CPT2 (0.42) RIPK1CPT2CPT1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3288939-A1 TRICYCLIC MODULATORS OF TNF SIGNALING AbbVie Inc. (US) 2018-03-07 — — EP claimed
US-20160304517-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. 2016-10-20 — — US claimed
WO-2016168641-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. (US) 2016-10-20 — — WO claimed
US-20260131007-A1 Mannose 6-Phosphate Receptor Binding Compounds for the Degradation of Extracellular Proteins AVILAR THERAPEUTICS, INC. (US) 2026-05-14 — — US disclosed
US-20260083851-A1 POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS AVILAR THERAPEUTICS, INC. (US) 2026-03-26 — — US disclosed
US-20250269043-A1 TARGETED BIFUNCTIONAL DEGRADERS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2025-08-28 — — US disclosed
EP-4493221-A2 TARGETED BIFUNCTIONAL DEGRADERS Yale University (US) 2025-01-22 — — EP disclosed
CN-119212727-A Targeted bifunctional degradants 耶鲁大学 2024-12-27 — — CN disclosed
WO-2024182772-A2 MANNOSE 6-PHOSPHATE RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-09-06 — — WO disclosed
WO-2024098039-A2 POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-05-10 — — WO disclosed
WO-2023178199-A2 TARGETED BIFUNCTIONAL DEGRADERS YALE UNIVERSITY (US) 2023-09-21 — — WO disclosed
US-20180179198-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. 2018-06-28 — — US disclosed
EP-3288939-A1 TRICYCLIC MODULATORS OF TNF SIGNALING AbbVie Inc. (US) 2018-03-07 — — EP disclosed
US-9856253-B2 Tricyclic modulators of TNF signaling ABBVIE, INC. (US) 2018-01-02 — — US disclosed
US-9856253-B2 Tricyclic modulators of TNF signaling ABBVIE, INC. (US) 2018-01-02 — — US disclosed
US-20160304517-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. 2016-10-20 — — US disclosed
US-20160304517-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. 2016-10-20 — — US disclosed
US-20160304517-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. 2016-10-20 — — US disclosed
WO-2016168641-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. (US) 2016-10-20 — — WO disclosed
WO-2016168641-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. (US) 2016-10-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250269043-A1 TARGETED BIFUNCTIONAL DEGRADERS SMURF2, SMURF1, MDM2 RIPK1 829/4885PIK3CB 3430/4885MTOR 2817/4885
US-20260083851-A1 POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS ASGR1, FCGR2A, FCGR3B RIPK1 3300/4885PIK3CB 3372/4885MTOR 4605/4885
US-20160304517-A1 TRICYCLIC MODULATORS OF TNF SIGNALING TNF, TNFRSF1A, CD40 RIPK1 199/4885PIK3CB 715/4885MTOR 89/4885
US-20260131007-A1 Mannose 6-Phosphate Receptor Binding Compounds for the Degradation of Extracellular Proteins IGF2R, M6PR, MSR1 RIPK1 2904/4885PIK3CB 2240/4885MTOR 2504/4885
US-20180179198-A1 TRICYCLIC MODULATORS OF TNF SIGNALING TNF, TNFRSF1A, CD40 RIPK1 199/4885PIK3CB 715/4885MTOR 89/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.